| |
Anti-La+ SS patients with HCV infection
|
Anti-La+ SS patients with no HCV infection
|
Bilateral P value
|
|---|
|
N = 17
|
N = 200
|
|---|
|
Mean age, years
|
59.59 ± 11.87
|
51.04 ± 15.77
|
0.03
|
|
Sex, male
|
4 (23 %)
|
8 (4 %)
|
0.009*
|
|
Dry mouth
|
16 (94 %)
|
197 (99 %)
|
0.280
|
|
Dry eye
|
17 (100 %)
|
196 (98 %)
|
1.000
|
|
Altered ocular tests
|
15/16 (94 %)
|
176/187 (94 %)
|
1.000
|
|
Altered parotid scintigraphy
|
9/10 (90 %)
|
151/165 (91 %)
|
0.602
|
|
Positive salivary gland biopsy
|
3/3 (100 %)
|
55/61 (90 %)
|
1.000
|
|
Antinuclear antibody+
|
14 (82 %)
|
170/199 (85 %)
|
0.723
|
|
Rheumatoid factor+
|
13/17 (77 %)
|
112/191 (59 %)
|
0.199
|
|
Anti-Ro/SS-A+
|
12 (71 %)
|
178 (89 %)
|
0.044
|
|
Monoclonal gammopathy
|
7/13 (54 %)
|
33/166 (20 %)
|
0.01
|
|
Type of monoclonal band
|
|
- mIgA
|
0 (0 %)
|
3 (9 %)
|
0.87
|
|
- mIgG
|
4 (57 %)
|
17 (52 %)
|
|
- mIgM
|
2 (29 %)
|
9 (27 %)
|
|
- Free chains
|
1 (14 %)
|
4 (12 %)
|
|
Type of monoclonal light chain
|
|
- Kappa:lambda
|
2:5
|
23:10
|
0.041
|
|
Cryoglobulin+
|
9 (53 %)
|
19/188 (10 %)
|
<0.001
|
|
Low C3 levels, <0.82 g/l
|
9 (53 %)
|
22/196 (11 %)
|
<0.001*
|
|
Low C4 levels, <0.11 g/l
|
11 (65 %)
|
14/196 (7 %)
|
<0.001*
|
|
Hematological neoplasia
|
0 (0 %)
|
7 (3.5 %)
|
1.000
|
|
Neoplasia
|
4 (23.5 %)
|
17 (8.5 %)
|
0.067
|
|
Death
|
7 (41 %)
|
16 (8 %)
|
0.001
|
- *Statistically significant in the multivariate model
-
SS Sjögren syndrome, HCV hepatitis C virus, SS-A Sjögren syndrome A antigen, mIg circulating monoclonal immunoglobulin, C3 complement component 3, C4 complement component 4Bold numbers: statistically-significant differences in the univariate analysis (p<0.05)
